Ryvu Therapeutics is entering a strategic agreement with BioNTech to benefit Polish cancer patients. The company will support trial site activation and patient recruitment for multiple investigational immunotherapies of BioNTech’s oncology pipeline in Poland.
The parties plan to leverage Ryvu’s operational excellence, expertise in oncology clinical operations and existing trial site network to streamline access of Polish patients to BioNTech’s investigational immunotherapies.
BioNTech intends to design and rollout clinical trials for some of the company’s priority programmes in Poland and fund Ryvu’s services under the agreement.
The clinical programmes planned to be included in the agreement span multiple solid tumour types, including lung, breast and colorectal cancer.
Kamil Sitarz, Chief Operating Officer, Management Board Member of Ryvu Therapeutics, said: "We are thrilled to build on our strong research relationship with BioNTech by entering a strategic agreement that leverages Ryvu’s operational excellence and expertise in oncology clinical operations to bring more BioNTech clinical programmes to Poland.”
“BioNTech’s science and innovation, combined with our shared ambition to bring innovative treatments to patients quickly, create a powerful momentum. We look forward to working together to streamline clinical trial activation and patient recruitment for BioNTech’s cancer immunotherapy clinical trials in Poland."